Sunshine Biopharma enters $4M ATM equity facility with Aegis Capital

Sunshine Biopharma Inc.

Up to $4M of common stock may be sold at-the-market through Aegis Capital as exclusive agent.
Aegis receives 3.0% commission on gross proceeds plus expense reimbursement.
Shares issued under existing S-3 shelf (File No. 333-284142) effective Jan 15, 2025.
No obligation to sell; Company controls timing and volume via placement notices.
Agreement can be terminated by either party per its terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.